General Information of Drug Transporter (DT)
DT ID	DTD0126 Transporter Info
Gene Name	SLC19A1
Protein Name	Folate transporter 1
Gene ID	6573
UniProt ID	P41440
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs1051266
Site of GPD	chr21:45537880 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	C=0.4886/2447 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:            2 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased vomiting in patients (compare with Allele T); Irrelevant to the differences in plasma or cerebrospinal fluid homocysteine levels or in toxicity in patients (compare with Allele T); Irrelevant to the drug response in patients (compare with Allele T)		[ 1], [ 2], [ 3]
Methotrexate	Drug Info	Leukemia	Irrelevant to the nephrotoxicity risk in patients (compare with Allele T); Irrelevant to the prolonged high drug concentrations risk patients (compare with Allele T)		[ 4]
Allele T	Click to Show/Hide the Full List of Affected Drugs:            5 Drugs in Total
Folic Acid	Drug Info	Rheumatoid Arthritis	Correlated with the increased drug response in patients (compare with allele C)		[ 5]
Sulfasalazine	Drug Info	Rheumatoid Arthritis	Correlated with the increased drug response in patients (compare with allele C)		[ 5]
Hydroxychloroquine	Drug Info	Rheumatoid Arthritis	Correlated with the increased drug response in patients (compare with allele C)		[ 5]
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the increased drug response in patients (compare with allele C); Correlated with the increased drug response in patients (compare with allele C); Irrelevant to the drug response in patients (compare with allele C)		[ 5], [ 6], [ 7]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the worse prognose in patients (compare with genotype CC)		[ 8]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:            9 Drugs in Total
Irinotecan	Drug Info	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with Genotypes CT + TT)		[ 9]
Fluorouracil	Drug Info	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with Genotypes CT + TT)		[ 9]
Leucovorin	Drug Info	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with Genotypes CT + TT)		[ 9]
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the increased drug toxicity risk in patients (compare with Genotypes CT + TT)		[ 10]
Mercaptopurine	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased likelihood of toxic liver disease in patients (compare with genotypes tt + Ct)		[ 11]
Leucovorin	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased likelihood of toxic liver disease in patients (compare with genotypes tt + Ct)		[ 11]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased likelihood of toxic liver disease in patients (compare with genotypes tt + Ct); Correlated with the increased severity of mucositis risk in patients (compare with Genotypes CT + TT)		[ 11], [ 12]
Methotrexate	Drug Info	Osteosarcoma	Correlated with the increased overall survival in patients (compare with Genotype TT)		[ 13]
Capecitabine	Drug Info	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with Genotypes CT + TT)		[ 9]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug response in patients (compare with Genotype TT)		[ 14]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:            8 Drugs in Total
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the decreased disease activity in patients (compare with genotypes CC + CT); Correlated with the decreased drug response in patients (compare with genotype CC); Correlated with the increased aminotransferase activity in patients (compare with genotypes CC + CT); Correlated with the increased likelihood of remission in patients (compare with genotype CC); Correlated with the increased methotrexate polyglutamate (mtXPG3-5) levels in patients (compare with genotypes CC + CT)		[ 6], [ 16], [ 17], [ 18]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased likelihood of myelosuppression in patients (compare with genotypes CC + CT); Correlated with the increased likelihood of staying in remission in patients (compare with genotypes CC + CT); Correlated with the increased likelihood of toxic liver disease in patients (compare with genotypes CC + CT); Correlated with the increased plasma drug levels in patients (compare with genotypes CC + CT); Irrelevant to the drug concentrations in patients (compare with genotypes CC + CT); Irrelevant to the drug toxicity risk in patients (compare with genotypes CC + CT)		[ 8], [ 11], [ 21], [ 22]
Mercaptopurine	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased likelihood of staying in remission in patients (compare with genotypes CC + CT)		[ 11]
Leucovorin	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased likelihood of staying in remission in patients (compare with genotypes CC + CT)		[ 11]
Methotrexate	Drug Info	Osteosarcoma	Correlated with the increased neoplasm metastasis risk in patients (compare with genotypes CC + CT)		[ 13]
Methotrexate	Drug Info	Lymphoma	Correlated with the increased toxic liver disease risk in patients (compare with genotype CC); Irrelevant to the increased drug concentrations in patients (compare with genotype CC)		[ 24]
Prednisone	Drug Info	Rheumatoid Arthritis	Correlated with the increased likelihood of remission in patients (compare with genotype CC)		[ 6]
Platinum compounds	N.A.	Non-Small-Cell Lung Carcinoma	Correlated with the decreased progression-free survival in patients (compare with genotypes CC + CT)		[ 25]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:            2 Drugs in Total
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the increased gastrointestinal toxicity risk in patients (compare with Genotype TT); Correlated with the increased severity of disease in patients (compare with Genotype TT)		[ 22], [ 23]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Irrelevant to the mucositis risk in patients (compare with Genotype TT)		[ 1]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:            3 Drugs in Total
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the decreased drug discontinuation in patients (compare with genotype CC); Correlated with the increased drug response in patients (compare with genotype CC)		[ 24], [ 25]
Mercaptopurine	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased drug toxicity risk in patients (compare with genotype CC)		[ 26]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased drug toxicity risk in patients (compare with genotype CC); Irrelevant to the drug concentrations in patients (compare with genotype CC)		[ 1], [ 26]
Genotypes TT + CT	Click to Show/Hide the Full List of Affected Drugs:            2 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased likelihood of drug toxicity in patients (compare with genotype CC)		[ 27]
Mercaptopurine	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased likelihood of drug toxicity in patients (compare with genotype CC); Correlated with the increased likelihood of treatment interruptions in patients (compare with genotype CC)		[ 27], [ 28]
Genetic Polymorphism	rs1051298
Site of GPD	chr21:45514912 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.4756/2382 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:            2 Drugs in Total
Pemetrexed	Drug Info	Lung Neoplasm	Correlated with the increased progression-free survival in patients (compare with Allele A)		[ 29]
Bevacizumab	N.A.	Lung Neoplasm	Correlated with the increased progression-free survival in patients (compare with Allele A)		[ 29]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Pemetrexed	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the decreased overall survival in patients (compare with genotype GG)		[ 30]
Genetic Polymorphism	rs12659
Site of GPD	chr21:45531642 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.4469/2238 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:            3 Drugs in Total
Fluorouracil	Drug Info	Uterine Cervical Neoplasm	Correlated with the decreased drug response in patients (compare with allele G)		[ 31]
Cisplatin	Drug Info	Uterine Cervical Neoplasm	Correlated with the decreased drug response in patients (compare with allele G)		[ 31]
Carboplatin	Drug Info	Uterine Cervical Neoplasm	Correlated with the decreased drug response in patients (compare with allele G)		[ 31]
Genetic Polymorphism	rs2838958
Site of GPD	chr21:45528653 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.4173/2090 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug response in patients (compare with genotypes AG + GG)		[ 1]
Genetic Polymorphism	rs9977268
Site of GPD	chr21:45487373 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.1587/795 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the increased likelihood of treatment inefficacy in patients (compare with allele C)		[ 7]
Genetic Polymorphism	rs3788189
Site of GPD	chr21:45516669 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>G
Minor Allele Frequency	T=0.4491/2249 (Global)
Genotypes GG + GT	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Pemetrexed	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the decreased overall survival in patients (compare with Genotype TT)		[ 30]
Genetic Polymorphism	rs914232
Site of GPD	chr21:45532836 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.4936/2472 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Pemetrexed	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the decreased overall survival in patients (compare with genotypes CC + CT)		[ 30]
References
1	Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia. Oncotarget. 2017 Jun 6;8(23):37761-37772.
2	Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2006 Feb;28(2):64-8.
3	Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol. 2003 Aug 15;21(16):3084-91.
4	Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy. Int J Hematol. 2013 Dec;98(6):702-7.
5	Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J Rheumatol. 2008 Apr;35(4):562-71.
6	Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J. 2007 Dec;7(6):404-7.
7	Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J. 2013 Jun;13(3):227-34.
8	Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood. 2002 Nov 15;100(10):3832-4.
9	SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer. PLoS One. 2013 Oct 15;8(10):e77223.
10	Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients. Int J Clin Pharmacol Ther. 2014 Sep;52(9):746-55.
11	The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood. 2010 Jun 10;115(23):4671-7.
12	Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. Pharmacogenomics J. 2012 Oct;12(5):379-85.
13	Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate. Pharmacogenomics J. 2015 Oct;15(5):385-90.
14	G80A Single Nucleotide Polymorphism in Reduced Folate Carrier-1 Gene in a Mexican Population and its Impact on Survival in Patients with Acute Lymphoblastic Leukemia. Rev Invest Clin. 2016 May-Jun;68(3):154-62.
15	Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004 Sep;50(9):2766-74.
16	Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis. J Clin Pharm Ther. 2009 Jun;34(3):355-61.
17	Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics. 2004 Nov;14(11):733-9.
18	Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet. 2007;52(2):166-71.
19	Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis. Leuk Lymphoma. 2014 Dec;55(12):2793-800.
20	Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics. 2014 Aug;15(11):1479-94.
21	Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients. Pharmacogenomics J. 2019 Apr;19(2):164-177.
22	SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients. Pharmacogenomics. 2014 Apr;15(6):807-20.
23	Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis. 2005 Aug;64(8):1180-5.
24	Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. Pharmacogenomics J. 2017 Oct;17(5):412-418.
25	Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis. Pharmacogenomics. 2015 Dec;16(18):2019-34.
26	Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL. Pharmacogenomics. 2012 Jul;13(9):1001-8.
27	Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007 May 15;109(10):4151-7.
28	Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2008 May;30(5):347-52.
29	Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol. 2010 Feb 1;28(4):614-9.
30	Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations. Pharmacogenomics J. 2014 Oct;14(5):411-7.
31	XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gynecol Oncol. 2006 Dec;103(3):1031-7.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.